Reduction in basic fibroblast growth factor mediated angiogenesis in vivo by linomide

Connective Tissue Research

Volumn 37, Issue 1-2, 1998, Pages 61-68

  Nagler, Arnon ^a   Feferman, Regina ^b   Shoshan, Shmuel ^b  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0031969932     PISSN: 03008207     EISSN: None     Source Type: Journal    
DOI: 10.3109/03008209809028900     Document Type: Article

References (42)

1. Ilback, N. G., Fohlman, J., Slorach, S. and Firman, G. (1989). Effects of the immunomodular LS 2616 on T-lymphocyte subpopulations in murine coxsackievirus B3 myocarditis. J. Immunol., 142, 3225-3228.
2. Larsson, E. L., Joki, A. and Stalhandske, T. (1987). Mechanism of action of the new immunomodulator LS 2616 on T-cell responses. Int. J. Immunopharmacol., 9, 425-431.
3. Kalland, T., Alm, G. and Stalhandske, T. (1985). Augmentation of mouse natural killer cell activity by LS 2616. a new immunomodulator. J. Immunol., 134, 3956-3961.
4. Kalland, T. (1990). Regulation of natural killer progenitors. J. Immunol., 144, 4472-4476.
5. Condiotti, R., Slavin, S., Barak, V. and Nagler, A. (1996). The novel immunomodulator, Linomide, stimulates interleukin-2 induced human natural killer (NK) cell and PHA-stimulated T-cell proliferation from normal donors. Leuk. Res., 20, 57-63.
6. Kalland, T.(1986). Effects of the immunomodulator LS 2616 on growth and metastasis of the murine B16-F10 melanoma. Cancer Res., 46, 3018-3022.
7. Harning, R., Koo, G. C. and Szalay, J. (1989). Regulation of the metastasis of murine ocular melanoma by natural killer cells. Invest. Ophtalmol. Pothalmol. Vis. Sci., 30, 1909-1915.
8. Harning, R., Koo, G. C. and Szalay, J. (1990). Immune regulation of metastasis from in vivo derived syngeneic murine melanoma. Reg. Immunol., 3, 97-102.
9. Kalland, T., Aim, G. and Stalhandske, T. (1985). Augmentation of mouse natural killer cell activity by LS 2616, a new immunomodulator. J. Immunol., 134, 3956-3961.
10. Ter-Grigorov, V., Slavin, S., Liubashevsky, E. and Trainin, S., Successful treatment of Rauscher retrovirus-induced leukemia in mice with the immunomodulator LS 2616. (submitted)
11. Stalhandske, T., Enksoo, E. and Sandberg, M. A. (1982). A novel quinolinecarboxamide with interesting immunomodulatory activity. Int. J. Immunopharmacol., 4, 336-341.
12. Ichikawa, T. M., Lamb, J. C., Christensson, P. J., Hartley-Asp. B. and Isaacs, J. T. (1992). The antitumor effects of the quinoline-3-carboxamide linomide on Dunning R-3327 rat prostatic cancers. Cancer Res., 52, 3022-3028.
13. Rowe, J. U., Ryan, D. H., Nilsson, B. I., Liesveld, J. L., DePersio, J. F., Rapport, A. P., Abbound, C. N., Larsson, L., Packman, C. H., Duerst, R. E. and Simonsson, B. (1994). Chronic myelogenous leukemia treated with autologous bone marrow transplantation followed by Roquinimex. Blood, 10, 204a (abst.).
14. Vukanovic, J., Passaniti, A., Hirata, T., Traystman, R. J., Hartley-Asp, B. and Isaacs, J. T. (1993) Antiangiogenic effects of the quinoline-3-carboxamide linomide. Cancer Res., 53, 1833-1837.
15. Vukanovic, J. and Isaacs, J. T. (1995). Human prostatic cancer cells are sensitive to programmed (apoptotic) death induced by the antiangiogenic agent linomide. Cancer Res, 55, 3517-3520.
16. Vukanovic, J., Hartley-Asp, B. and Isaacs, J. T. (1995). Inhibition of tumor angiogenesis and the therapeutic ability of linomide against rat prostatic cancers. Prostate, 26, 235-246.
17. Vukanovic, J. and Isaacs, J. T. (1995). Linomide inhibits angiogenesis, growth, metastasis, and macrophage infiltration within rat prostatic cancers. Cancer Res, 55, 1499-1504.
18. Borgstrom, P., Torres. Filho, I. P. and Hartley-Asp, B. (1995). Inhibition of angiogenesis and metastasis of the Lewis-lung cell carcinoma by the quinoline-3-carboxamide, Linomide. Anticancer Res, 15, 719-728.
19. Joseph, I. B., Vukanovic, J. and Isaacs, J. T. (1996). Antiangiogenic treatment with linomide as chemoprevention for prostate, seminal vesicle, and breast carcinogenesis in rodents. Cancer Res, 56, 3404-3408.
20. Folkman, J. (1985). Towards an understanding of angiogenesis: search and discovery. Perspectives, in Biology and Medicine, 29, 1-36.
21. Folkman, J. and Klagsbrun, M. (1987). Angiogenic factors. Science, 235, 442-447.
22. Folkman, J. and Shing, Y. (1992). Angiogenesis. J. Biol. Chem., 267, 10,931-10,934.
23. Gospodarowicz, D., Cheng, J. and Lui, G. M. (1984). Isolation of brain fibroblast growth factor by heparin-sepharose affinity chromography: identity with pituitary fibroblast growth factor. Proc. Natl. Acad. Sci., 81, 6963-6967.
24. Gospodarowicz, D., Moran, J., Braun, D. and Birdwell, C. R. (1976). Clonal growth of bovine vascular endothelial cells in tissue culture: fibroblast growth factor as a survival agent. Proc. Natl. Acad. Sci., 73, 4120-4124.
25. Vlodavsky, I., Liu, G. M. and Gospodarowicz, D. (1980). Morphological appearance, growth behavior and migratory activity of human tumor cells maintained on extracellular matrix vs. plastic. Cell, 19, 607-616.
26. Vlodavsky, I., Folkman, J., Sullivan, R., Friedman, R., Ishai-Michaeli, R., Sasse, J. and Klagsbrun, M. (1987). Endothelial cell-derived basic fibroblast growth factor: synthesis and deposition into subendothelial extracellular matrix. Proc. Natl. Acad. Sci., 84, 2292-2296.
27. Burton, K. (1968). Determination of DNA concentration with diphenyl amine. Meth. Enzymol., XII-B, 163-166.
28. Bradford, M. M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analyt. Biochem., 72, 248-254.
29. Stegemann, H. and Stalder, K. (1967). Determination of hydroxyproline. Clin. Chim. Acta, 18, 267-273.
30. Neuman, R. E. and Logan, M. H. (1950). The determination of collagen and elastin in tissue. J. Biol. Chem., 186, 549-556.
31. Deujanov, I. (1987). Biology of disease. Lectin cytochemistry and histochemistry. Lab. Invest., 57, 5-20.
32. Kivela, T. (1990). Characterization of galactose-containing glycoconjugates in the human retina: a lectin histochemical study. Current Eye. Res., 9, 1195-1209.
33. Marani, A. (1972). Methods of planning and conduction of experiments., (Academon Press, Jerusalem), pp 33.
34. Borgstrom, P., Torres Filho, I. P., Vajkoczy, P., Strandgarden, K., Polacek, J. and Hartley-Asp, B. (1994). The quinoline-3-carboxamide linomide inhibits angiogenesis in vivo. Cancer Chemother Pharmacol., 34, 280-286.
35. Joseph, I. B. and Isaacs, J. T. (1996). The antiangiogenic agent linomide inhibits tumor necrosis factor-alpha secretion via inhibition of its synthesis. Prostate, 19, 183-190.
36. Parenti, A., Donnini, S., Morbidelli, L., Granger, H. J. and Ziehe, M. (1996). The effect of linomide on the migration and the proliferation of capillary endothelial cells elicited by vascular endothelial growth factor. Br. J. Pharmacol. 119, 619-621.
37. Bischoll, J. (1995). Approaches to studying cell adhesion molecules in angiogenesis. Trends. Cell. Biol., 5, 69-74.
38. Iruela-Arispe, M. L. and Hasselaar, P. (1991). Differential expression of extra-cellular proteins in correlation with angiogenesis in vitro. Lab. Invest., 64, 174-186.
39. Jackson, C. J. and Jenkins, K. L. (1991). Type I collagen fibrils promote rapid vascular tube formation upon contact with the apical side of cultured endothelium. Exp. Cell Res., 192, 319-323.
40. Slavin, S., Naparstek, E., Nagler, A., Ackerstein, A., Samuel, S., Kapelushnik, J., Brautbar, C. and Or, R. (1996). Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood, 87, 2195-2204.
41. Slavin, S., Naparstek, E., Nagler, A., Ackerstein, A., Kapelushnik, J. and Or, R. (1995). Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheal blood lymphocytes. Exp. Hematol., 23, 1553-1562.
42. Nagler, A., Ackerstein, A., Or, R., Naparstek, E. and Slavin, S. (1997). Immunotherapy with recombinant human interleukin-2 (rIL-2) and recombinant alpha interferon (αIFN) in lymphoma patients post-autologous marrow or stem cell transplantation. Blood , 89, 3951-3959.